



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 376 358
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 89202720.2

(51) Int. Cl.⁵: C07D 211/34, C07D 405/06,
C07D 401/06, C07D 409/06,
C07D 405/12, C07D 401/12,
C07D 409/12, A61K 31/445

(22) Date of filing: 26.10.89

(30) Priority: 01.11.88 GB 8825505

(72) Inventor: Cross, Peter Edward
21 Cherry Avenue
Canterbury Kent(GB)
Inventor: MacKenzie, Alexander Roderick
48, St. Leonards Road
Deal Kent, CT14 9AU(GB)

(43) Date of publication of application:
04.07.90 Bulletin 90/27


(74) Representative: Wood, David John et al
PFIZER LIMITED, Ramsgate Road
Sandwich, Kent CT13 9NJ(GB)

(38) Designated Contracting States:
ES GR

(71) Applicant: PFIZER INC.
235 East 42nd Street
New York, N.Y. 10017(US)


(54) Muscarinic receptor antagonists.

(57) A compound of the formula:-




or a pharmaceutically acceptable salt thereof,
wherein Y is a direct link, -CH₂, -(CH₂)₂-, -CH₂O- or -CH₂S-;
R is -CN or -CONH₂;
and R¹ is a group of the formula:-

EP 0 376 358 A1



,



where R² and R³ are each independently H, C₁-C₄ alkyl, C₁-C₄ alkoxy, -(CH₂)_nOH, halo, trifluoromethyl, cyano, -(CH₂)_nNR⁴R⁵, -CO(C₁-C₄ alkyl), -OCO(C₁-C₄ alkyl), -CH(OH)(C₁-C₄ alkyl), -C(OH)(C₁-C₄ alkyl)₂, -SO₂NH₂, -(CH₂)_nCONR⁴R⁵ or -(CH₂)_nCOO(C₁-C₄ alkyl);

R⁴ and R⁵ are each independently H or C₁-C₄ alkyl;

n is 0, 1 or 2;

X and X' are each independently O or CH₂;

m is 1, 2 or 3;

and "Het" is pyridyl, pyrazinyl or thieryl.


The compounds are muscarinic receptor antagonists useful in the treatment of diseases associated with the altered motility and/or tone of smooth muscle, especially irritable bowel syndrome.

MUSCARINIC RECEPTOR ANTAGONISTS

This invention relates to certain 3-substituted piperidine derivatives. The compounds of the invention are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites and which do not have any significant antihistaminic activity. Thus the compounds are useful in the treatment of diseases associated with altered motility and/or tone of smooth muscle which can, 5 for example, be found in the gut, trachea and bladder. Such diseases include irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.

According to the invention there are provided compounds of the formula:-

10



15

and their pharmaceutically acceptable salts, wherein Y is a direct link, -CH₂-, -(CH₂)₂-, -CH₂O- or -CH₂S-;

R is -CH or -CONH₂;

20 and R¹ is a group of the formula:-

25



30 where R² and R³ are each independently H, C₁-C₄ alkyl, C₁-C₄ alkoxy, -(CH₂)_nOH, halo, trifluoromethyl, cyano, -(CH₂)_nNR⁴R⁵, -CO(C₁-C₄ alkyl), -OCO(C₁-C₄ alkyl), -CH(OH)(C₁-C₄ alkyl), -C(OH)(C₁-C₄ alkyl)₂, -SO₂NH₂, -(CH₂)_nCONR⁴R⁵ or -(CH₂)_nCOO(C₁-C₄ alkyl);

R⁴ and R⁵ are each independently H or C₁-C₄ alkyl;

n is 0, 1 or 2;

X and X¹ are each independently O or CH₂;

35 m is 1, 2 or 3;

and "Het" is pyridyl, pyrazinyl or thienyl.


"Halo" means F, Cl, Br or I. Alkyl and alkoxy groups of 3 or 4 carbon atoms can be straight or branched chain. The preferred alkyl and alkoxy groups are methyl, ethyl, methoxy and ethoxy.

R is preferably -CONH₂.

40 m is preferably 1.


R¹ is preferably a group of the formula:-

45



50 where R² and R³ are each independently selected from H, halo, hydroxy, hydroxymethyl, C₁-C₄ alkyl, C₁-C₄ alkoxy and carbamoyl, and X and X¹ are as defined above.

R¹ is most preferably:-



5

γ is preferably a direct link, $-\text{CH}_2-$, $-(\text{CH}_2)_2-$ or $-\text{CH}_2\text{O}-$.

Y is more preferably a direct link, $-\text{CH}_2-$ or $-(\text{CH}_2)_2-$.

Y is most preferably -CH₂-.


The anticholinergic activity of the present compounds resides substantially in the 3R-forms, i.e., the compounds having R stereochemistry at position 3 of the piperidine ring, hence the preferred compounds are the 3R- and 3R,S-(racemic) forms of the compounds (I).

The pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts such as the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, besylate, citrate, fumarate, gluconate, lactate, maleate, mesylate, succinate and tartrate salts. For a more comprehensive list of pharmaceutically acceptable salts see, for example, the Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977, pages 1-19. These salts can be prepared conventionally, e.g. by mixing a solution of the free base and the acid in a suitable solvent, e.g. ethanol, and recovering the acid addition salt either as a precipitate, or by evaporation of the solution.

The compounds of the formula (I) can be prepared by a number of routes, including the following:-

Route A

25 This can be illustrated as follows:-



Y, R are R¹ are as defined for formula (I) and Q is a leaving group, e.g. Br, Cl, I, C₁-C₄ alkanesulfonyloxy (e.g. methanesulfonyloxy), benzenesulfonyloxy, toluenesulfonyloxy (e.g. p-toluenesulfonyloxy) or trifluoromethanesulfonyloxy. Preferably, Q is Cl, Br, I or methanesulfonyloxy.

The reaction is preferably carried out in the presence of an acid acceptor such as sodium or potassium carbonate, triethylamine or pyridine, and in a suitable organic solvent, e.g. acetonitrile, at up to the reflux temperature. Reaction temperatures of 60-120 °C are generally desirable and it is most convenient to carry out the reaction under reflux. Iodo is often a particularly suitable leaving group but since the starting materials (III) are sometimes most conveniently available as chlorides the reaction can also be carried out using the compound (III) as a chloride but in the presence of an iodide such as sodium or potassium iodide. In the preferred technique, the compounds (II) and (III) are refluxed together in acetonitrile in the presence of potassium carbonate or sodium bicarbonate. The product (I) can be isolated and purified conventionally.

The 3R,S- or 3R- forms of the starting material (II) are preferably used so as to obtain the preferred 50 3R,S- or 3R- forms of the product.

The starting materials of the formula (II) can be obtained by conventional procedures such as those described in Preparations 1 and 2, and in EP-A-178946 and 178947. The starting materials of the formula (III) are in general known compounds which can be prepared by conventional techniques. The preparation of any novel starting materials of the formula (III) used in the Examples is however described in the following Preparations section.

Route B

The compounds of the formula (I) in which R is -CONH₂ can be prepared by the hydrolysis of the corresponding nitriles, e.g. using concentrated aqueous mineral acid (typically concentrated aqueous H₂SO₄).


5 The hydrolysis is typically carried out using concentrated aqueous sulphuric acid, preferably 80-98% sulphuric acid and most preferably 90% H₂SO₄, with heating at e.g. 80-110 °C and most preferably at about 100 °C. The product can then be isolated and purified by conventional procedures. Clearly any cyano substituents on R¹ are also likely to be hydrolysed to carbamoyl or carboxy, any alkanoyloxy substituents to hydroxy, and any alkoxy carbonyl substituents to carboxy.

10

Route C

This route is useful for preparing compounds in which Y is -CH₂- and R¹ is 2- or 4-pyridyl or pyrazinyl and can be described as follows:-

15



35

R is as defined for formula (I). Clearly the vinyl group must be attached to the 2- or 4-position of the pyridine ring.

The reaction is typically carried out with heating, e.g. at about 60 ° to 110 °C and preferably under reflux, in a suitable organic solvent, e.g. dioxan. In some instances, the use of a basic (preferably a strong base which is soluble in an organic solvent such as N-benzyltrimethylammonium hydroxide ["Triton B"]) or acidic (preferably a C₁-C₄ alkanoic acid) catalyst may be beneficial.

40 Some of the compounds of the formula (I) in which R¹ is a substituted phenyl group can be converted to other compounds of the formula (I) as follows:-

(a) When R is -CONH₂, a -CO₂(C₁-C₄ alkyl) substituent on the phenyl group can be selectively reduced to -CH₂OH. Lithium aluminium hydride is the most suitable reducing agent. The reaction is typically carried in a suitable organic solvent, e.g. ether, at between 0 ° and room temperature. It is generally most convenient to use the starting material in the form of its methyl ester.

(b) A hydroxy substituent on the phenyl group can be converted to -OCO(C₁-C₄ alkyl) by acylation using a C₁-C₄ alkanoyl chloride or bromide, or an alkanoic anhydride of the formula (C₁-C₄ alkyl.CO)₂O. The presence of an acid acceptor is preferable. The reaction is typically carried out at about room temperature in a suitable organic solvent, e.g. dioxan.

50 (c) A -CO(C₁-C₄ alkyl) substituent on the phenyl group can be reduced to a substituent of the formula -CH(OH)(C₁-C₄ alkyl). A suitable reducing agent is sodium borohydride. The reaction is typically carried out at between 0 ° and room temperature in a suitable organic solvent, e.g. methanol.

(d) When R is -CONH₂, a -(CH₂)_nCOO(C₁-C₄ alkyl) substituent, preferably where the alkyl group is methyl, can be converted to -(CH₂)_nCONR⁴R⁵ by reaction with ammonia or the appropriate amine R⁴R⁵NH. When R⁴ and R⁵ are both H, the use of aqueous (0.880) ammonia is generally most convenient, although the reaction can be carried out using ammonia in an organic solvent such as methanol or ethanol, or ammonia neat in a bomb. The reaction with methylamine is most conveniently carried out in ethanol.

Although in some instances the reaction may proceed at a satisfactory rate at room temperature, heating at up to 120 °C, preferably 60 to 100 °C, is generally necessary. For volatile amines, the reaction is best carried out in a bomb.

(e) A hydroxy substituent can be converted to C₁-C₄ alkoxy firstly by reaction with a base such as 5 potassium carbonate, and secondly by reaction with a C₁-C₄ alkyl iodide or bromide. The reaction is typically carried out in a solvent such as dioxan or acetone, and preferably under reflux.

(f) A hydroxymethyl or hydroxyethyl substituent on the phenyl group can be converted to -CH₂NR⁴R⁵ or -(CH₂)₂NR⁴R⁵ firstly by reaction with thionyl chloride and secondly by reaction with ammonia or the appropriate amine R⁴R⁵NH. The reaction with thionyl chloride is typically carried out with heating, 10 preferably under reflux, in a solvent such as methylene chloride. The reaction with ammonia or the amine is typically carried out at in a solvent such as ethanol, and heating, e.g. under reflux, may be necessary.

(g) When A is -CONH₂, a -CO(C₁-C₄ alkyl) substituent can be converted to -C(OH)(C₁-C₄ alkyl)₂ by 15 reaction with a C₁-C₄ alkyl lithium or C₁-C₄ alkylmagnesium bromide, chloride, or iodide (e.g. methyl lithium, methylmagnesium bromide, methylmagnesium iodide or methylmagnesium chloride). The reaction is typically carried out in a solvent such as ether at a temperature of from 0 °C to room temperature. and

(h) An iodo substituent can be converted to C₁-C₄ alkoxy carbonyl by reaction, typically at about room temperature, with carbon monoxide in a C₁-C₄ alkanol containing a base [e.g. potassium carbonate] and a palladium (II) catalyst [e.g. bis(triphenylphosphine)palladium (II) chloride].

20 The selectivity of the compounds as muscarinic receptor antagonists can be measured as follows.

Male guinea pigs are sacrificed and the ileum, trachea, bladder and right atrium are removed and suspended in physiological salt solution under a resting tension of 1 g at 32 °C aerated with 95% O₂ and 5% CO₂. Contractions of the ileum, bladder and trachea are recorded using an isotonic (ileum) or isometric transducer (bladder and trachea). The frequency of contraction of the spontaneously beating right atrium is 25 derived from isometrically recorded contractions.

Dose-response curves to either acetylcholine (ileum) or carbachol (trachea, bladder and right atrium) are determined using a 1-5 minute contact time for each dose of agonist until the maximum response is achieved. The organ bath is drained and refilled with physiological salt solution containing the lowest dose 30 of the test compound. The test compound is allowed to equilibrate with the tissue for 20 minutes and the agonist dose-response curve is repeated until the maximum response is obtained. The organ bath is drained and refilled with physiological salt solution containing the second concentration of test compound and the above procedure is repeated. Typically four concentrations of the test compound are evaluated on each tissue.

The concentration of the test compound which causes a doubling of the agonist concentration to 35 produce the original response is determined (pA₂ value - Arunlakshana and Schild (1959), Brit. J. Pharmacol., 14, 48-58). Using the above analytical techniques, tissue selectivity for muscarinic receptor antagonists is determined.

Activity against agonist induced bronchoconstriction or gut or bladder contractility in comparison with changes in heart rate is determined in the anaesthetised dog. Oral activity is assessed in the conscious dog 40 determining compound effects on, for example, heart rate, pupil diameter and gut motility.

Compound affinity for other cholinergic sites is assessed in the mouse after either intravenous or intraperitoneal administration. Thus, the dose which causes a doubling of pupil size is determined as well as the dose which inhibits the salivation and tremor responses to intravenous oxotremorine by 50%.

For administration to man in the curative or prophylactic treatment of diseases associated with the 45 altered motility and/or tone of smooth muscle, such as irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease, oral dosages of the compounds will generally be in the range of from 3.5 to 350 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules will typically contain from 1 to 250 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier for administration singly or in 50 multiple doses, once or several times a day. Dosages for intravenous administration will typically be within the range 0.35 to 35 mg per single dose as required. In practice the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the 55 scope of this invention.

For human use, the compounds of the formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they may be administered orally in the

form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.

In a further aspect the invention provides a pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

The invention also includes a compound of the formula (I) or a pharmaceutically acceptable salt thereof, for use as a medicament, particularly for use in the treatment of irritable bowel syndrome.

The invention further includes the use of a compound of the formula (I), or of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diseases associated with the altered motility and/or tone of smooth muscle, such as irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.

The invention yet further includes a method of treatment of a human being to cure or prevent a disease associated with the altered motility and/or tone of smooth muscle, such as irritable bowel syndrome, which comprises treating said human being with an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or composition thereof.


The following Examples, in which all temperatures are in °C, illustrate the invention:

20

EXAMPLE 1

25

Preparation of 1-(4-chlorophenethyl)-3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine



45

A mixture containing 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine (1 g - see Preparation 1), 4-chlorophenethyl bromide (0.72 g), anhydrous potassium carbonate (1.5 g) and acetonitrile (25 ml) was heated under reflux for 4 hours. The mixture was partitioned between dichloromethane (50 ml) and 10% aqueous potassium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (3 x 30 ml). The combined dichloromethane extracts were dried (MgSO₄) and concentrated *in vacuo* to give an oil which was purified by column chromatography on silica eluting with hexane containing dichloromethane (30% up to 70%) and then dichloromethane containing methanol (0% up to 5%). The product-containing fractions were combined and concentrated *in vacuo* to give an oil which was crystallised from acetonitrile to give the title compound as colourless rhombs, yield 0.85 g, m.p. 129-131 °C, [α]_D²⁵ + 20.3 (c 1.0, CH₂Cl₂).

Analysis %:-			
Found:	C,77.89; C,78.14;	H,6.58; H,6.56;	N,6.84; N,6.75.
Calculated for C ₂₇ H ₂₇ N ₂ Cl:			

5

¹H N.m.r. (CDCl₃) δ = 7.60-7.05 (m, 14H); 3.10-3.00 (d, 1H); 2.95-2.80 (m, 2H); 2.75-2.50 (m, 4H); 2.15-2.00 (m, 2H); 1.85-1.60 (m, 3H); 1.50-1.30 (m, 1H) ppm.


10

EXAMPLE 2

15

Preparation of 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)-1-phenethylpiperidine

20



25

30

35

40

45

A mixture containing 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine (1 g), phenethyl bromide (0.67 g), anhydrous potassium carbonate (1.5 g) and acetonitrile (25 ml) was heated under reflux for 4 hours. The mixture was partitioned between dichloromethane (50 ml) and 10% aqueous potassium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (3 x 30 ml). The combined dichloromethane extracts were dried (MgSO₄) and concentrated in vacuo to give an oil which was purified by column chromatography on silica eluting with hexane containing dichloromethane (30% up to 70%) then dichloromethane containing methanol (0% up to 5%). The product-containing fractions were combined and concentrated in vacuo to give an oil which was crystallised from acetonitrile to give the title compound as colourless rhombs, yield 0.72 g, m.p. 134-138 °C, [α]_D²⁵ + 13.3° (c 1.0, CH₂Cl₂).

50


Analysis %:-			
Found:	C,84.74; C,85.22;	H,7.44; H,7.42;	N,7.91; N,7.36.
Calculated for C ₂₇ H ₂₈ N ₂ :			

¹H N.m.r. (CDCl₃) δ = 7.60-7.10 (m, 15H); 3.10-3.00 (m, 1H); 2.95-2.55 (m, 5H); 2.20-2.00 (m, 3H); 1.85-1.60 (m, 3H); 1.50-1.35 (m, 1H) ppm.

55

EXAMPLE 3

Preparation of 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]piperidine



20 A mixture containing 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine (1.09 g), 5-(2-bromoethyl)-2,3-dihydrobenzofuran (0.9 g - see Preparation 5), anhydrous potassium carbonate (1.1 g) and acetonitrile (25 ml) was heated under reflux for 5 hours. The mixture was partitioned between dichloromethane (50 ml) and 10% aqueous potassium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 50 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated *in vacuo* to give an oil which was purified by column chromatography on silica eluting with hexane containing dichloromethane (30% up to 70%) then dichloromethane containing methanol (0% up to 5%). The product-containing fractions were combined and concentrated *in vacuo* to give an oil which was crystallised from acetonitrile to give the title compound as colourless rhombs, yield 0.64 g, m.p. 137-140 °C, $[\alpha]_D^{25} + 13.7^\circ$ (c 1.0, CH_2Cl_2).


Analysis %:-

Found:	C,82.49;	H,7.25;	N,6.74;
Calculated for C ₂₉ H ₃₀ N ₂ O:	C,82.42;	H,7.16;	N,6.63.

¹H N.m.r. (CDCl₃)δ = 7.70-7.25 (m, 10H); 7.00 (s, 1H); 6.90 (d, 1H); 6.70 (d, 1H); 4.65-4.50 (m, 2H); 3.25-3.15 (m, 2H); 3.10-3.00 (m, 1H); 2.95-2.80 (m, 2H); 2.75-2.50 (m, 4H); 2.15-2.00 (m, 2H); 1.85-1.60 (m, 3H); 1.50-1.35 (m, 1H) ppm.

EXAMPLE 4

Preparation of 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)-1-(4-hydroxymethylphenethyl)piperidine



20 A mixture containing 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine (0.28 g), 4-hydroxymethylphenethyl bromide (0.22 g), anhydrous potassium carbonate (0.28 g) and acetonitrile (10 ml) was heated under reflux for 5 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous potassium carbonate (20 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 20 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated *in vacuo* to give an oil which was purified by column chromatography on silica eluting with hexane containing dichloromethane (30% up to 70%) then dichloromethane containing methanol (0% up to 5%). The product-containing fractions were combined and concentrated *in vacuo* to give an oil which was crystallised from acetonitrile to give the title compound as colourless rhombs, yield 0.21 g, m.p. 110-114 °C, $[\alpha]_D^{25} + 16.2^\circ$ (c 1.0, CH_2Cl_2).

25

30

Analysis %:-			
Found:	C,81.90; C,81.91;	H,7.50; H,7.36;	N,7.44; N,6.82.
Calculated for $\text{C}_{28}\text{H}_{30}\text{N}_2\text{O}$:			


35 $^1\text{H N.m.r. (CDCl}_3\delta = 7.60\text{-}7.50$ (m, 4H); 7.45-7.25 (m, 8H); 7.15 (d, 2H); 4.65 (s, 2H); 3.10-3.00 (d, 1H); 2.95-2.50 (m, 6H); 2.15-1.90 (m, 3H); 1.85-1.60 (m, 3H); 1.50-1.30 (m, 1H) ppm.

40 EXAMPLE 5

45

50 Preparation of 3-(R)-(1-cyano-1,1-diphenylmethyl)-1-[2-(indan-5-yl)ethyl]piperidine

55



A mixture containing 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine (0.28 g), 5-(2-bromoethyl)indane (0.23 g - see Preparation 4), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 5 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous potassium carbonate (20 ml), the layers separated, and the aqueous layer extracted with dichloromethane (3 x 20 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated *in vacuo* to give a gum which was purified by column chromatography on silica eluting with hexane containing dichloromethane (30% up to 70%) then dichloromethane containing methanol (0% up to 5%). The product-containing fractions were combined and concentrated *in vacuo* to give an oil which was crystallised from acetonitrile to give the title compound as colourless rhombs, yield 0.13 g, m.p. 88-91 °C.

Analysis %:-				
30	Found: Calculated for $\text{C}_{30}\text{H}_{32}\text{N}_2$:	C,85.81; C,85.67;	H,7.57; H,7.67;	N,6.78; N,6.66.

35 ^1H N.m.r. (CDCl_3) δ = 7.60-7.50 (m, 4H); 7.45-7.25 (m, 6H); 7.15 (d, 1H); 7.05 (s, 1H); 6.90 (d, 1H); 3.10-3.00 (d, 1H); 2.95-2.80 (m, 6H); 2.75-2.50 (m, 5H); 2.15-2.00 (m, 3H); 1.95-1.65 (m, 3H); 1.50-1.35 (m, 1H) ppm.

EXAMPLE 6


40

Preparation of 3-(R)-(1-cyano-1,1-diphenylmethyl)-1-(3-methylphenethyl)piperidine

45

50

55



20 A mixture containing 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine (0.28 g), 3-methylphenethyl bromide (0.2 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 5 hours. The mixture was partitioned between dichloromethane (70 ml) and 10% aqueous potassium carbonate (10 ml), the layers separated and the aqueous layer extracted with dichloromethane (2×70 ml).
 25 The combined dichloromethane extracts were dried ($MgSO_4$) and concentrated *in vacuo* to give an oil which was purified by column chromatography on silica eluting with hexane containing dichloromethane (70% up to 100%) then dichloromethane containing methanol (4%). The product-containing fractions were combined and concentrated *in vacuo* to give an oil which was crystallised from acetonitrile to give the title compound as colourless rhombs, yield 0.127 g, m.p. 149-150 °C.

Analysis %:-				
30	Found: Calculated for $C_{28}H_{30}N_2$:	C,85.23; C,85.18;	H,7.66; H,7.63;	N,7.10; N,7.04.

35 1H N.m.r. ($CDCl_3$) δ = 7.60-7.50 (m, 4H); 7.40-7.25 (m, 6H); 7.20-7.15 (m, 1H); 7.05-6.90 (m, 3H); 3.10-3.00 (m, 1H); 2.95-2.85 (m, 2H); 2.75-2.50 (m, 4H); 2.35 (s, 3H); 2.15-2.00 (m, 2H); 1.85-1.65 (m, 3H); 1.50-1.35 (m, 1H) ppm.

EXAMPLE 7


40

Preparation of 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)-1-(4-methylphenethyl)piperidine

45

50

55



A mixture containing 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine (1 g), 4-methylphenethyl bromide (0.72 g), anhydrous potassium carbonate (1.5 g) and acetonitrile (25 ml) was heated under reflux for 5 hours. The mixture was partitioned between dichloromethane (50 ml) and 10% aqueous potassium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (3 x 30 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated in vacuo to give an oil which was purified by column chromatography on silica eluting with hexane containing dichloromethane (30% up to 70%) then dichloromethane containing methanol (0% up to 5%). The product-containing fractions were combined and concentrated in vacuo to give an oil which was crystallised from acetonitrile to give the title compound as colourless rhombs, yield 1 g, m.p. 110-113 °C, $[\alpha]_D^{25} + 14.7$ (c 1.0, CH_2Cl_2).

Analysis %:-				
30	Found: Calculated for $\text{C}_{28}\text{H}_{30}\text{N}_2$	C,85.54; C,82.24;	H,7.68; H,7.66;	N,7.37; N,7.14.

35 ^1H N.m.r. (CDCl_3) $\delta = 7.60\text{-}7.50$ (m, 4H); 7.40-7.25 (m, 6H); 7.15-7.00 (m, 4H); 3.10-2.80 (m, 3H); 2.80-2.50 (m, 4H); 2.35 (s, 3H); 2.15-2.00 (m, 2H); 1.85-1.65 (m, 3H); 1.50-1.35 (m, 1H) ppm.

EXAMPLE 8


40

Preparation of 3-(R)-(1-cyano-1,1-diphenylmethyl)-1-(3,4-dichlorophenethyl)piperidine

45

50

55



A mixture containing 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine (0.28 g), 3,4-dichlorophenethyl bromide (0.255 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 8 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous potassium carbonate (20 ml), the layers separated and the aqueous layer extracted with dichloromethane (3 x 70 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated in vacuo to give an oil which was purified by column chromatography on silica eluting with dichloromethane containing hexane (30%). The product-containing fractions were combined and concentrated in vacuo to give an oil which was crystallised from acetonitrile to give the title compound, yield 0.233 g, m.p. 139-142 °C.


Analysis %:-			
Found:	C,72.04; H,6.18; N,6.80;		
Calculated for $\text{C}_{27}\text{H}_{26}\text{Cl}_2\text{N}_2$:	C,72.15; H,5.83; N,6.24.		

¹H N.m.r. (CDCl_3) δ = 7.65-7.20 (m, 12H); 7.00 (dd, 1H); 3.10-2.50 (m, 7H); 2.20-2.00 (m, 2H); 1.85-1.60 (m, 3H); 1.50-1.30 (m, 1H) ppm.

EXAMPLE 9

40

Preparation of 3-(R,S)-(1-cyano-1,1-diphenylmethyl)-1-(3-phenylpropyl)piperidine



A mixture containing 3-(R,S)-(1-cyano-1,1-diphenylmethyl)piperidine (0.3 g - see EP-A-0178947), 1-bromo-3-phenylpropane (0.238 g), anhydrous potassium carbonate (0.4 g) and acetonitrile (10 ml) was heated under reflux for 5 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous potassium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 20 ml). The combined dichloromethane extracts were dried ($MgSO_4$) and concentrated in vacuo to give a gum which was purified by column chromatography on silica eluting with dichloromethane containing methanol (0% up to 2%). The product-containing fractions were combined and concentrated in vacuo to give the title compound as a gum, yield 0.4 g.

10

Analysis %:-			
Found:	C,84.83; C,85.23;	H,7.67; H,7.67;	N,7.06; N,7.10.
Calculated for $C_{28}H_{30}N_2$:			

15

1H N.m.r. ($CDCl_3$) δ = 7.60-7.10 (m, 15H); 3.00-2.80 (m, 3H); 2.65-2.50 (m, 2H); 2.40-2.30 (m, 2H); 2.10-1.90 (m, 2H); 1.85-1.55 (m, 4H); 1.50-1.30 (m, 2H) ppm.

20

EXAMPLE 10

25

Preparation of 3-(R,S)-(1-cyano-1,1-diphenylmethyl)-1-(4-hydroxyphenethyl)-piperidine


30

35

40

45

50



A mixture containing 3-(R,S)-(1-cyano-1,1-diphenylmethyl)piperidine (0.4 g), 4-hydroxyphenethyl bromide (0.32 g), sodium bicarbonate (0.5 g) and acetonitrile (15 ml) was heated under reflux for 4 hours. The mixture was concentrated in vacuo and the residue partitioned between dichloromethane (50 ml) and 10% aqueous potassium carbonate (50 ml). The layers were separated and the aqueous layer extracted with dichloromethane (3 x 20 ml). The combined dichloromethane extracts were dried ($MgSO_4$) and concentrated in vacuo to give a gum which was purified by column chromatography on silica eluting with dichloromethane containing methanol (5%). The product-containing fractions were combined and concentrated in vacuo to give the title compound as a gum, yield 0.267 g.

55

Analysis %:-			
Found:	C,80.48; C,80.36;	H,7.07; H,7.02;	N,6.91; N,6.92.
Calculated for $C_{27}H_{28}N_2O.1/10 CH_2Cl_2$:			

1H N.m.r. ($CDCl_3$) δ = 7.60-7.45 (m, 4H); 7.40-7.25 (m, 6H); 7.95 (d, 2H); 6.70 (d, 2H); 3.15-3.05 (d, 1H);


3.00-2.90 (m, 2H); 2.75-2.55 (m, 4H); 2.20-2.00 (m, 3H); 1.85-1.65 (m, 4H); 1.50-1.30 (m, 1H) ppm.

EXAMPLE 11

5

Preparation of 3-(R,S)-(1-cyano-1,1-diphenylmethyl)-1-(4-carbamoylphenethyl)piperidine

10



25

A mixture containing 3-(R,S)-(1-cyano-1,1-diphenylmethyl)piperidine (0.303 g), 4-carbamoylphenethyl bromide (0.275 g - see Preparation 5), anhydrous potassium carbonate (0.4 g) and acetonitrile (10 ml) was heated under reflux for 5 hours. The mixture was concentrated in vacuo and the residue partitioned between dichloromethane (50 ml) and 10% aqueous potassium carbonate (50 ml). The layers were separated and the aqueous layer extracted with dichloromethane (3 x 20 ml). The combined dichloromethane extracts were dried ($MgSO_4$) and concentrated in vacuo to give a gum which was purified by column chromatography on silica eluting with dichloromethane containing methanol (5%). The product-containing fractions were combined and concentrated in vacuo to give the title compound as a gum, yield 0.065 g.

35

40

Analysis %:-			
Found:	C,78.91;	H,6.93;	N,9.96;
Calculated for $C_{28}H_{29}N_3O$:	C,78.66;	H,6.84;	N,9.83.

1H N.m.r. ($CDCl_3$) δ = 7.80-7.70 (d, 2H); 7.60-7.45 (m, 4H); 7.40-7.20 (m, 8H); 6.05 (brs, 1H); 5.60 (brs, 1H); 3.10-2.55 (m, 6H); 2.15-2.00 (m, 2H); 1.85-1.60 (m, 4H); 1.50-1.35 (m, 1H) ppm.


45

EXAMPLE 12

50

Preparation of 3-(R,S)-(1-cyano-1,1-diphenylmethyl)-1-(4-methoxyphenethyl)piperidine

55



A mixture containing 3-(R,S)-(1-cyano-1,1-diphenylmethyl)piperidine (0.27 g), 4-methoxyphenethyl bromide (0.21 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 16 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous sodium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 30 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated in vacuo to give a gum which was purified by column chromatography on silica eluting with dichloromethane containing methanol (0% up to 2%). The product-containing fractions were combined and concentrated in vacuo to give the title compound as a gum, yield 0.3 g.


Analysis %:-				
Found:	C,81.78;	H,7.33;	N,6.82;	
Calculated for $\text{C}_{28}\text{H}_{30}\text{N}_2\text{O}$:	C,81.91;	H,7.36;	N,6.82.	

30 ^1H N.m.r. (CDCl_3) δ = 7.60-7.45 (m, 4H); 7.40-7.25 (m, 6H); 7.05 (d, 2H); 6.85 (d, 2H); 3.80 (s, 3H); 3.10-3.00 (brd, 1H); 2.95-2.80 (m, 2H); 2.70-2.50 (m, 4H); 2.15-2.00 (m, 2H); 1.85-1.60 (m, 3H); 1.50-1.35 (m, 1H) ppm.

35

EXAMPLE 13

40 Preparation of 3-(R,S)-(1-cyano-1,1-diphenylmethyl)-1-(3,4-methylenedioxybenzyl)piperidine



A mixture containing 3-(R,S)-(1-cyano-1,1-diphenylmethyl)piperidine (0.27 g), 3,4-methylenedioxybenzyl chloride (0.18 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 16 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous sodium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 30 ml).

5 The combined dichloromethane extracts were dried ($MgSO_4$) and concentrated in vacuo to give a gum which was purified by column chromatography on silica eluting with dichloromethane containing methanol (0% up to 2%). The product-containing fractions were combined and concentrated in vacuo to give the title compound as a colourless solid, yield 0.2 g, m.p. 127-130 °C.

10

Analysis %:-			
Found:	C,79.29; H,6.48; N,6.69;		
Calculated for $C_{27}H_{26}N_2O_2$:	C,78.99; H,6.38; N,6.82.		

15

1H N.m.r. ($CDCl_3$) δ = 7.55-7.20 (m, 10H); 6.85 (s, 1H); 6.75-6.65 (m, 2H); 5.95 (s, 2H); 3.20 (s, 2H); 2.90-2.75 (m, 3H); 2.10-1.90 (m, 2H); 1.75-1.55 (m, 3H); 1.50-1.30 (m, 1H) ppm.


20

EXAMPLE 14

25

Preparation of 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-(3,4-methylenedioxybenzyl)piperidine

30:



35

40

45 A mixture containing 3-(R,S)-1-carbamoyl-1,1-diphenylmethyl)piperidine (0.26 g - see Preparation 2), 3,4-methylenedioxybenzyl chloride (0.18 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 6 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous sodium carbonate (20 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 30 ml). The combined dichloromethane extracts were dried ($MgSO_4$) and concentrated in vacuo to give a solid which was recrystallised from ethanol to give the title compound, yield 0.21 g, m.p. 190-195 °C.

55

Analysis %:-			
Found:	C,75.51; H,6.70; N,6.17;		
Calculated for $C_{27}H_{28}N_2O_3$:	C,75.67; H,6.58; N,6.54.		

¹H N.m.r. (CDCl₃) δ = 7.50-7.20 (m, 10H); 6.90 (s, 1H); 6.75 (s, 2H); 5.95 (s, 2H); 5.50 (s, 2H); 3.35 (s, 2H); 3.20-3.00 (m, 2H); 2.90-2.80 (m, 1H); 1.95-1.90 (d, 1H); 1.85-1.60 (m, 3H); 1.40-1.25 (m, 1H); 0.95-0.75 (m, 1H) ppm.

5

EXAMPLE 15


10

Preparation of 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenethyl)piperidine

15

20

25



30

A mixture containing 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)piperidine (0.26 g), 4-methoxyphenethyl bromide (0.22 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 16 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous sodium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 30 ml). The combined dichloromethane extracts were dried (MgSO₄) and concentrated in vacuo to give a solid which was recrystallised from ethanol to give the title compound, yield 0.05 g, m.p. 153-156° C.

35

40

45

Analysis %:-			
Found:	C,78.69;	H,7.53;	N,6.22;
Calculated for C ₂₈ H ₃₂ N ₂ O ₂ :	C,78.47;	H,7.53;	N,6.54.


¹H N.m.r. (CDCl₃) δ = 7.50-7.20 (m, 10H); 7.10 (d, 2H); 6.85 (d, 2H); 5.55-5.40 (brs, 2H); 3.80 (s, 3H); 3.25-3.10 (m, 2H); 3.00-2.90 (m, 1H); 2.80-2.65 (m, 2H); 2.60-2.40 (m, 2H); 2.00-1.90 (d, 1H); 1.90-1.65 (m, 3H); 1.50-1.35 (t, 1H); 0.95-0.80 (m, 1H) ppm.

EXAMPLE 16

50

Preparation of 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-[3-(4-methoxyphenyl)propyl]piperidine

55



15 A mixture containing 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)piperidine (0.26 g), 1-bromo-3-(4-methoxyphenyl)propane (0.23 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 16 hours. The mixture was partitioned between dichloromethane (30 ml) and 10 % aqueous sodium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 30 ml). The dichloromethane extracts were combined, dried (MgSO_4) and concentrated in vacuo to give a solid which was recrystallised from ethanol to give the title compound, yield 0.19 g, m.p. 180-182 °C.

20

Analysis %:-

25 Found: C,77.73; H,7.77; N,6.23;
calculated for $\text{C}_{29}\text{H}_{34}\text{N}_2\text{O}_2 \cdot 1/4 \text{H}_2\text{O}$: C,78.07; H,7.80; N,6.28.


35 ^1H N.m.r. (CDCl_3) δ = 7.50-7.25 (m, 10H); 7.10 (d, 2H); 6.85 (d, 2H); 5.50 (brs, 2H); 3.80 (s, 3H); 3.20-3.05 (m, 2H); 2.90 (m, 1H); 2.60-2.55 (t, 2H); 2.30-2.20 (t, 2H); 2.00-1.90 (m, 1H); 1.80-1.60 (m, 5H); 1.40-1.30 (m, 1H); 0.90-0.75 (m, 1H) ppm.

EXAMPLE 17

35

Preparation of 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methylphenethyl)piperidine

40



55 A mixture containing 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)piperidine (0.26 g), 4-methylphenethyl bromide (0.2 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 4.5 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous sodium

carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 30 ml). The combined dichloromethane extracts were dried ($MgSO_4$) and concentrated in vacuo to give a colourless solid which was recrystallised from methanol to give the title compound, yield 0.13 g, m.p. 167-169 °C.

5

Analysis %:-			
Found:	C,81.36; C,81.51;	H,7.62; H,7.82;	N,6.75; N,6.80.
Calculated for $C_{28}H_{32}N_2O$:			

10

1H N.m.r. ($CDCl_3$) δ = 7.50-7.25 (m, 10H); 7.10 (s, 4H); 5.50-5.40 (brd, 2H); 3.20-3.10 (m, 2H); 3.00-2.95 (d, 1H); 2.75-2.70 (m, 2H); 2.55-2.45 (m, 2H); 2.35 (s, 3H); 2.00-1.90 (d, 1H); 1.90-1.65 (m, 3H); 1.50-1.40 (t, 1H); 0.95-0.80 (m, 1H) ppm.


15

EXAMPLE 18

20

Preparation of 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-phenethylpiperidine

25



30

35

40

A mixture containing 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)piperidine (0.3 g), phenethyl bromide (0.2 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (10 ml) was heated under reflux for 7 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous sodium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 30 ml). The combined dichloromethane extracts were dried ($MgSO_4$) and concentrated in vacuo to give a colourless solid which was recrystallised from aqueous ethanol to give the title compound, yield, 0.17 g, m.p. 175-178 °C.

45

Analysis %:-			
Found:	C,81.00; C,81.37;	H,7.62; H,7.58;	N,7.00; N,7.03.
Calculated for $C_{27}H_{30}N_2O$:			


50

1H N.m.r. ($CDCl_3$) δ = 7.50-7.15 (m, 15H); 5.55-5.45 (brd, 2H); 3.25-3.10 (m, 2H); 3.05-2.95 (m, 1H); 2.80-2.70 (m, 2H); 2.60-2.50 (m, 2H); 2.00-1.90 (d, 1H); 1.85-1.70 (m, 3H); 1.50-1.40 (t, 1H); 0.95-0.80 (m, 1H) ppm.

55

EXAMPLE 19

Preparation of 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-carbamoylphenethyl)piperidine




A mixture containing 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)piperidine (0.3 g), 4-carbamoylphenethyl bromide (0.23 g - see Preparation 5), sodium bicarbonate (0.3 g) and acetonitrile (15 ml) was heated under reflux for 7 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous sodium carbonate (30 ml). The layers were separated and the aqueous layer extracted with dichloromethane (2 x 30 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated *in vacuo* to give an oil which was purified by column chromatography on silica eluting with dichloromethane containing methanol (0% up to 6%). The product-containing fractions were combined and concentrated *in vacuo* to give a colourless solid which was recrystallised from ethanol/ethyl acetate, yield 0.09 g, m.p. 208 °C.

Analysis %:-			
Found:	C,75.24;	H,7.37;	N,9.30;
Calculated for C ₂₈ H ₃₁ N ₃ O ₂ .1/4 H ₂ O:	C,75.39;	H,7.11;	N,9.42.

³⁵ ¹H N.m.r. (CDCl₃) δ = 7.70 (d, 2H); 7.35-7.10 (m, 12H); 6.80 (brs, 1H); 5.95 (brs, 1H); 5.85 (brs, 1H); 5.55 (brs, 1H); 3.10-3.00 (m, 2H); 2.90-2.80 (m, 1H); 2.75-2.65 (m, 2H); 2.45-2.35 (m, 2H); 1.90-1.80 (d, 1H); 1.70-1.50 (m, 3H); 1.30-1.20 (t, 1H); 1.80-1.60 (m, 1H) ppm.

EXAMPLE 20

Preparation of 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-chlorophenethyl)piperidine




A mixture containing 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)piperidine (0.3 g), 4-chlorophenethyl bromide (0.24 g), anhydrous potassium carbonate (0.3 g) and acetonitrile (15 ml) was heated under reflux for 7 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous sodium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 50 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated in vacuo to give a solid which was recrystallised from aqueous methanol to give the title compound, yield 0.24 g, m.p. 188-190 °C.

Analysis %:-				
10	Found:	C,74.57; C,74.89;	H,6.79; N,6.75;	N,6.43; N,6.47.
	Calculated for $\text{C}_{27}\text{H}_{29}\text{ClN}_2\text{O}$:			

15 ^1H N.m.r. (CDCl_3) δ = 7.50-7.20 (m, 12H); 7.10 (d, 2H); 5.55-5.40 (brs, 2H); 3.20-3.05 (m, 2H); 3.00-2.90 (m, 1H); 2.80-2.65 (m, 2H); 2.55-2.40 (m, 2H); 2.00-1.90 (d, 1H); 1.85-1.65 (m, 3H); 1.45-1.35 (t, 1H); 0.90-0.80 (m, 1H) ppm.

20 EXAMPLE 21

25 Preparation of 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-hydroxyphenethyl)piperidine



40 A mixture containing 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)piperidine (0.3 g), 4-hydroxyphenethyl bromide (0.21 g), sodium bicarbonate (0.3 g) and acetonitrile (15 ml) was heated under reflux for 5 hours. The mixture was partitioned between dichloromethane (30 ml) and 10% aqueous sodium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 50 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated in vacuo to give a gum which was purified by column chromatography, firstly on silica eluting with dichloromethane containing methanol (0% up to 6%), and then on alumina eluting with dichloromethane containing methanol (0% up to 10%). The product-containing fractions were combined and concentrated in vacuo to give the title compound as colourless microcrystals, yield 0.042 g, m.p. 135-140 °C.

45

Analysis %:-				
50	Found:	C,73.81; C,74.41;	H,7.04; H,6.94;	N,6.28; N,6.43.
	Calculated for $\text{C}_{27}\text{H}_{30}\text{N}_2\text{O}_2 \cdot 1/4 \text{CH}_2\text{Cl}_2$:			

55

^1H N.m.r. (CDCl_3) δ = 7.45-7.25 (m, 10H); 7.00 (d, 2H); 6.75 (d, 2H); 5.70-5.50 (m, 2H); 3.30-3.15 (m, 2H); 3.10-3.00 (d, 1H); 2.80-2.60 (m, 2H); 2.60-2.45 (m, 2H); 2.00-1.65 (m, 5H); 1.55-1.45 (t, 1H); 0.90-0.75 (m,


1H) ppm.

EXAMPLE 22

5

Preparation of 3-(R)-(1-cyano-1,1-diphenylmethyl)-1-(2-phenoxyethyl)piperidine

10



30 A mixture containing 3-(R)-(1-cyano-1,1-diphenylmethyl)piperidine (0.3 g), 2-phenoxyethyl bromide (0.24 g - commercially available), anhydrous potassium carbonate (0.5 g) and acetonitrile (15 ml) was heated under reflux for 5 hours. The mixture was then partitioned between dichloromethane (30 ml) and 10% aqueous potassium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 20 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated *in vacuo* to give a gum which was purified by column chromatography on silica eluting with dichloromethane containing methanol (0% up to 2%). The product-containing fractions were combined and concentrated *in vacuo* to give the title compound as a gum, yield 0.254 g.

35

40

Analysis %:-			
Found:	C,81.73; H,7.19; N,7.16;		
Calculated for $\text{C}_{27}\text{H}_{28}\text{N}_2\text{O}$:	C,81.78; H,7.12; N,7.07.		


45 ^1H N.m.r. (CDCl_3) δ = 7.60-7.50 (m, 4H); 7.40-7.25 (m, 8H); 7.00-6.90 (t, 1H); 6.85-6.80 (d, 2H); 4.05-4.00 (t, 2H); 3.10-2.85 (m, 4H); 2.80-2.75 (t, 2H); 2.25-2.10 (m, 2H); 1.80-1.65 (m, 2H); 1.50-1.35 (m, 1H) ppm.

EXAMPLE 23

50

Preparation of 3-(R)-(1-cyano-1,1-diphenylmethyl)-1-(4-hydroxy-3-methoxyphenethyl)piperidine

55



A mixture containing 3-(R)-(1-cyano-1,1-diphenylmethyl)piperidine (0.3 g), 4-hydroxy-3-methoxyphenethyl chloride (0.223 g - see Preparation 6), anhydrous potassium carbonate (0.5 g), potassium iodide (0.2 g) and acetonitrile (15 ml) was heated under reflux for 5 hours. The mixture was partitioned between dichloromethane (40 ml) and 10% aqueous potassium carbonate (30 ml), the layers separated, and the aqueous layer extracted with dichloromethane (2 x 30 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated *in vacuo* to give a foam which was purified by column chromatography on silica eluting with dichloromethane containing methanol (5%). The product-containing fractions were combined and concentrated *in vacuo* to give a gum which was crystallised from acetonitrile to give the title compound as colourless rhombs, yield 0.132 g, m.p. 159-160°.


Analysis %:-				
Found:	C,77.50; C,77.61;	H,7.10; H,7.20;	N,7.84; N,7.94.	
Calculated for $\text{C}_{28}\text{H}_{30}\text{N}_2\text{O}_2 \cdot \frac{1}{2}$ CH_3CN :				

35 ^1H N.m.r. (CDCl_3) δ = 7.60-7.50 (m, 3H); 7.40-7.30 (m, 7H); 6.85-6.80 (d, 1H); 6.70-6.60 (m, 2H); 5.55 (brs, 1H); 3.90 (s, 3H); 3.10-2.50 (m, 8H); 2.15-2.05 (m, 1H); 1.80-1.60 (m, 3H); 1.45-1.35 (m, 1H) ppm.

The following Preparations illustrate the preparation of certain starting materials used in previous Examples:-

40 Preparation 1

45 (A) Preparation of 1-tosyl-3-(R)-(+)-tosyloxypiperidine




Para-toluenesulphonyl chloride (69 g) was added, in portions, to a solution of 3-(R)-(+)-hydroxypiperidine-(1S)-(+)-10-camphorsulphonate (45 g - see J. Chem. Soc., Perkin II, 697 [1981]) in

anhydrous pyridine (200 ml) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 24 hours. The solution was concentrated in vacuo to approximately half the original volume then partitioned between dichloromethane (300 ml) and water (200 ml). The layers were separated and the aqueous layer extracted with dichloromethane (3 x 100 ml). The combined dichloromethane extracts were washed with 2M hydrochloric acid (100 ml) and 10% aqueous sodium hydroxide (100 ml) then dried (MgSO_4) and concentrated in vacuo to give an oil which was crystallised from ether to give the title compound, yield 24 g, m.p. 140-147 °C, $[\alpha]_D^{25} + 60.7^\circ$ (c 1.0, CH_2Cl_2).
¹H N.m.r. (CDCl_3) δ = 7.85-7.80 (d, 2H); 7.65-7.60 (d, 2H); 7.40-7.30 (m, 4H); 4.60-4.50 (m, 1H); 3.50-3.40 (m, 1H); 3.35-3.25 (m, 1H); 2.75-2.60 (m, 2H); 2.50 (s, 3H); 2.45 (s, 3H); 1.90-1.75 (m, 2H); 1.65-1.50 (m, 2H) ppm.

(B) Preparation of 3-(R)-(-)-(1-cyano-1,1-diphenylmethyl)-1-tosylpiperidine

15

20



25

Diphenylacetonitrile (13.5 g) was added to a stirred suspension of sodium hydride (3.2 g of a 60% suspension in mineral oil) in anhydrous toluene (250 ml) and the mixture was heated under reflux for 2 hours. On cooling to room temperature, 1-tosyl-3-(R)-(+)-tosyloxypiperidine (23 g) was added in portions and the mixture heated under reflux for 4 hours. The mixture was diluted with toluene (200 ml) and washed with 10% sodium hydroxide (2 x 100 ml) and brine (100 ml) then dried (MgSO_4) and concentrated in vacuo to give an oil which was purified by column chromatography on silica eluting with toluene containing ethyl acetate (0% up to 10%). The product-containing fractions were combined and concentrated in vacuo to give an oil which was crystallised from ethanol to give the title compound, yield 16 g, m.p. 148-150 °C, $[\alpha]_D^{25} -94.4^\circ$ (c 1.0, CH_2Cl_2).

35

Analysis %:-			
Found:	C,72.44;	H,6.16;	N,6.43;
Calculated for $\text{C}_{26}\text{H}_{26}\text{N}_2\text{O}_2\text{S}$:	C,72.52;	H,6.08;	N,6.51.

40


¹H N.m.r. (CDCl_3) δ = 7.60-7.25 (m, 14H); 3.95-3.85 (d, 2H); 2.95-2.85 (brt; 1H); 2.45 (s, 3H); 2.35-2.25 (m, 2H); 1.85-1.65 (m, 3H); 1.45-1.30 (m, 1H) ppm.

45

(C) Preparation of 3-(R)-(+)-(1-cyano-1,1-diphenylmethyl)piperidine

50

55



A solution of 3-(R)-(-)-(1-cyano-1,1-diphenylmethyl)-1-tosylpiperidine (15 g) and phenol (15 g) in 48% aqueous hydrobromic acid (170 ml) was heated under reflux for 2 hours. The mixture was cooled to 0 °C in

an ice bath and basified (pH 12) by slow addition of 50% aqueous sodium hydroxide (200 ml). Methanol (10 ml) was added and the mixture stirred for 15 minutes then diluted with water (300 ml). The mixture was extracted with dichloromethane (4 x 150 ml), the combined extracts dried (MgSO_4) and concentrated in vacuo to give an oil. The oil was dissolved in 1:1 hexane/toluene (500 ml) and the solution extracted with 0.5 M hydrochloric acid (1500 ml). The aqueous extracts, together with some insoluble gum formed in the extraction, were basified (pH 12) by the addition of aqueous sodium hydroxide (100 g in 100 ml water) and the mixture extracted with dichloromethane (3 x 200 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated in vacuo to give the title compound as a gum, yield 9.9 g, $[\alpha]_D^{25} + 7.4^\circ$ (c 1.0, CH_2Cl_2).

10 $^1\text{H N.m.r.}$ (CDCl_3) $\delta = 7.60\text{-}7.20$ (m, 10H); 3.10-2.95 (m, 2H); 2.80-2.60 (m, 3H); 1.80-1.50 (m, 5H) ppm.


The methods used in this Preparation generally follow those described in EP-A-178946/7. 3-(R,S)-(1-cyano-1,1-diphenylmethyl)piperidine, described in EP-A-178947, was prepared similarly but using 3-(R,S)-hydroxypiperidine in part (A) in place of 3-(R)-(+)-hydroxypiperidine-(1S)-(+)-10-camphorsulphonate.

15

Preparation 2

20 Preparation of 3-(1-carbamoyl-1,1-diphenylmethyl)piperidine [see also EP-A-0178947]

25



30

A solution of 3-(1-cyano-1,1-diphenylmethyl)piperidine (4 g -see EP-A-0178947) in 90% sulphuric acid (22 ml) was heated at 100 °C for 2 hours. The mixture was poured onto ice (100 g) and basified with 35% aqueous sodium hydroxide (100 ml) then extracted with dichloromethane (3 x 100 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated in vacuo to give an oil which was crystallised from ether to give the title compound, yield 2.8 g, m.p. 200-210 °C.

35

Analysis %:-				
Found:	C,75.45; C,75.21;	H,7.41; H,7.64;	N,9.54; N,9.23.	
Calculated for $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_2$. H_2O :				

45


$^1\text{H N.m.r.}$ (CDCl_3) $\delta = 7.50\text{-}7.25$ (m, 10H), 5.65-5.50 (brs, 2H), 3.30-3.20 (d, 1H), 3.10-2.95 (m, 2H); 2.40-2.25 (m, 1H), 2.10-1.90 (m, 2H), 1.80-1.70 (brs, 1H), 1.70-1.60 (m, 2H), 1.00-0.85 (m, 1H) ppm.

50

Preparation 3

55

Preparation of 5-(2-bromoethyl)indane



Phosphorus tribromide (3.5 ml) was added, dropwise, to a solution of 5-(2-hydroxyethyl)indane (14.0 g) (FA-A-2139628) in carbon tetrachloride (100 ml). The mixture was stirred at room temperature for 0.5 hour and then heated under reflux for 2 hours. Ice (100 g) was added and the mixture partitioned between dichloromethane and 10% aqueous sodium carbonate. The layers were separated and the aqueous layer extracted with dichloromethane (2 x 100 ml). The combined dichloromethane extracts were dried (MgSO_4) and concentrated *in vacuo* to give an oil which was purified by column chromatography on silica eluting with dichloromethane. The product-containing fractions were combined and concentrated *in vacuo* to give the title compound as a colourless oil, yield 10.5 g.

10

15


$^1\text{H N.m.r. (CDCl}_3\text{)} \delta = 7.30\text{-}7.00 (\text{m, 3H}); 3.60 (\text{m, 2H}); 3.20 (\text{m, 2H}); 3.00\text{-}2.85 (\text{m, 4H}); 2.20\text{-}2.05 (\text{m, 2H})$ ppm.

20

Preparation 4

25

(A) Preparation of 5-(2-hydroxyethyl)-2,3-dihydrobenzofuran




A solution of (2,3-dihydrobenzofuran-5-yl)acetic acid (4.9 g - see EP-A-132130) in anhydrous tetrahydrofuran (50 ml) was added dropwise over 10 minutes to a stirred suspension of lithium aluminium hydride (1.57 g) in anhydrous tetrahydrofuran (50 ml) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 1 hour. Water (1.5 ml) was cautiously added dropwise followed by 10% aqueous sodium hydroxide (1.5 ml) and, finally, water (4.5 ml). The mixture was filtered and the inorganic salts washed with ethyl acetate (2 x 50 ml). The filtrate and washings were combined and concentrated *in vacuo* to give the title compound as an oil, yield 3.3 g.

35

40

$^1\text{H N.m.r. (CDCl}_3\text{)} \delta = 7.10 (\text{s, 1H}); 7.00 (\text{d, 1H}); 6.75 (\text{m, 1H}); 4.65\text{-}4.55 (\text{m, 2H}); 3.90\text{-}3.75 (\text{m, 2H}); 3.30\text{-}3.15 (\text{m, 2H}); 2.90\text{-}2.80 (\text{m, 2H}); 1.85\text{-}1.75 (\text{brs, 1H})$ ppm.

45 (B) Preparation of 5-(2-bromoethyl)-2,3-dihydrobenzofuran



55 Phosphorus tribromide (0.37 g) was added to a solution of 5-(2-hydroxyethyl)-2,3-dihydrobenzofuran (0.612 g) in carbon tetrachloride (3 ml) and the mixture heated under reflux for 3 hours. On cooling to room temperature, the mixture was partitioned between 10% aqueous sodium carbonate (20 ml) and dichloromethane (20 ml). The layers were separated and the aqueous layer extracted with dichloromethane (2 x

10 ml). The combined dichloromethane extracts were dried ($MgSO_4$) and concentrated in vacuo to give the title compound as an oil which crystallised on standing, yield 0.584 g, m.p. 60-62 °C.
 1H N.m.r. ($CDCl_3$) δ = 7.10 (s, 1H); 7.00-6.95 (d, 1H); 6.80-6.70 (d, 1H); 4.65-4.55 (t, 2H); 3.60-3.50 (t, 2H); 3.25-3.15 (t, 2H); 3.15-3.10 (t, 2H) ppm.

5

Preparation 5


10

Preparation of 4-carbamoylphenethyl bromide

15

20

25



30 A solution of phosphorus tribromide (5 g) in carbon tetrachloride (10 ml) was added, dropwise, to a solution of 4-cyanophenethyl alcohol (8.06 g) in carbon tetrachloride (60 ml). The mixture was heated under reflux for 4 hours. On cooling to room temperature, the mixture was poured onto ice (200 g). The layer were separated and the organic layer was washed with 10% aqueous sodium carbonate (50 ml) and brine (50 ml), dried ($MgSO_4$) and concentrated in vacuo to give a colourless oil which solidified on standing. The solid was chromatographed on silica eluting with ethyl acetate containing hexane (20%). The fractions containing the less polar (higher Rf) product were combined and concentrated in vacuo to give 4-cyanophenethyl bromide as a yellow oil which solidified on standard, yield 8.9 g. The fractions containing the more polar (lower Rf) product were combined and concentrated in vacuo to give the title compound as a colourless solid, yield 0.47 g, m.p. 152-153 °C.
 1H N.m.r. ($CDCl_3$) δ = 7.85 (d, 2H); 7.35 (d, 2H); 6.20-5.70 (brd, 2H); 3.70-3.60 (m, 2H); 3.35-3.20 (m, 2H) ppm.

40


Preparation 6

45

Preparation of 4-hydroxy-3-methoxyphenethyl chloride

50

55




Thionyl chloride (0.5 ml) was added, dropwise, to a stirred solution of 4-hydroxy-3-methoxyphenethyl alcohol (0.83 g -commercially available) in dichloromethane (50 ml). When the addition was complete, the

mixture was heated under reflux for 3 hours. On cooling to room temperature, the mixture was concentrated in vacuo to give a gum which was purified by column chromatography on silica eluting with dichloromethane containing methanol (0% up to 2%). The product-containing fractions were combined and concentrated in vacuo to give the title compound as an oil, yield 0.36 g.

5 ¹H N.M.R. (CDCl_3) δ 6.90 (d, 1H); 6.75 (m, 2H); 5.60 (brs, 1H); 3.90 (s, 3H); 3.70 (t, 2H); 3.05 (t, 2H) ppm.

Claims

10 1. A compound of the formula:-



20 or a pharmaceutically acceptable salt thereof,
wherein Y is a direct link, $-\text{CH}_2-$, $-(\text{CH}_2)_2-$, $-\text{CH}_2\text{O}-$ or $-\text{CH}_2\text{S}-$;
R is $-\text{CN}$ or $-\text{CONH}_2$;
and R¹ is a group of the formula:-



where R² and R³ are each independently H, C₁-C₄ alkyl, C₁-C₄ alkoxy, $-(\text{CH}_2)_n\text{OH}$, halo, trifluoromethyl, cyano, $-(\text{CH}_2)_n\text{NR}^4\text{R}^5$, $-\text{CO}(\text{C}_1\text{-C}_4\text{ alkyl})$, $-\text{OCO}(\text{C}_1\text{-C}_4\text{ alkyl})$, $-\text{CH}(\text{OH})(\text{C}_1\text{-C}_4\text{ alkyl})$, $-\text{C}(\text{OH})(\text{C}_1\text{-C}_4\text{ alkyl})_2$, $-\text{SO}_2\text{NH}_2$, $-(\text{CH}_2)_n\text{CONR}^4\text{R}^5$ or $-(\text{CH}_2)_n\text{COO}(\text{C}_1\text{-C}_4\text{ alkyl})$;

35 R⁴ and R⁵ are each independently H or C₁-C₄ alkyl;
n is 0, 1 or 2;
X and X¹ are each independently O or CH₂;

m is 1, 2 or 3;
and "Het" is pyridyl, pyrazinyl or thiienyl.

40 2. A compound as claimed in claim 1 wherein R¹ is selected from:-

(a)



wherein R² and R³ are each independently selected from H, halo, hydroxy, hydroxymethyl, C₁-C₄ alkyl, C₁-C₄ alkoxy, and carbamoyl, and


50 (b)



wherein X and X¹ are each independently O or CH₂.

3. A compound as claimed in claim 2 wherein R¹ is:-

5



4. A compound as claimed in any one of the preceding claims wherein Y is a direct link, -CH₂-, -(CH₂)₂- or -CH₂O-.

5. A compound as claimed in claim 4 wherein Y is -CH₂-.

6. A compound as claimed in any one of the preceding claims which is in the 3R- or 3RS- form.

7. A compound as claimed in claim 6 which is in the 3R-form.

8. A compound as claimed in claim 1 which is 3-(R)-(1-cyano-1,1-diphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]piperidine, 3-(R)-(1-cyano-1,1-diphenylmethyl)-1-[2-(indan-5-yl)ethyl]piperidine or 3-(R,S)-(1-carbamoyl-1,1-diphenylmethyl)-1-(3,4-methylenedioxybenzyl)piperidine.

9. A pharmaceutical composition comprising a compound of the formula (I) as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.


10. A compound of the formula (I) as claimed in any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use as a medicament.

11. The use of a compound of the formula (I) as claimed in any one of claims 1 to 8, or of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating diseases associated with the altered motility and/or tone of smooth muscle, such as irritable bowel syndrome.

12. The 3R form of a compound of the formula:-

25

30




35 where R is as defined in claim 1.

13. A process for preparing a compound of the formula:-

40

--- (I)



45

or a pharmaceutically acceptable salt thereof,
wherein Y is a direct link, -CH₂-, -(CH₂)₂-, -CH₂O- or -CH₂S-;

R is -CN or -CONH₂;

and R¹ is a group of the formula:-

50

55




where R² and R³ are each independently H, C₁-C₄ alkyl, C₁-C₄ alkoxy, -(CH₂)_nOH, halo, trifluoromethyl,

cyano, $-(CH_2)_nNR^4R^5$, $-CO(C_1-C_4\text{ alkyl})$, $-OCO(C_1-C_4\text{ alkyl})$, $-CH(OH)(C_1-C_4\text{ alkyl})$, $-C(OH)(C_1-C_4\text{ alkyl})_2$, $-SO_2NH_2$, $-(CH_2)_nCONR^4R^5$ or $-(CH_2)_nCOO(C_1-C_4\text{ alkyl})$;
 R^4 and R^5 are each independently H or C_1-C_4 alkyl;
 n is 0, 1 or 2;


5 X and X' are each independently O or CH_2 ;
 m is 1, 2 or 3;
and "Het" is pyridyl, pyrazinyl or thienyl,
characterised by carrying out one of the following reactions:-
(a) reacting a compound of the formula:-

10

15



20 with a compound of the formula:-



where R, R^1 and Y are as defined above and Q is a leaving group;

(b) to prepare a compound in which R is $-CONH_2$, hydrolysing the corresponding compound of the formula (I) in which R is $-CN$; and

25 (c) to prepare a compound in which Y is $-CH_2-$ and R^1 is 2- or 4-pyridyl or pyrazinyl, reacting a compound of the formula (II) as defined above with 2- or 4-vinylpyridine or 2-vinylpyrazine;
said reactions (a) to (c) being followed by, optionally, one or more of the following steps:-
(i) when R is $-CONH_2$, reducing a $-CO_2(C_1-C_4\text{ alkyl})$ substituent on a phenyl group represented by R^1 to $-CH_2OH$;

30 (ii) converting a hydroxy substituent on a phenyl group represented by R^1 to $-OCO(C_1-C_4\text{ alkyl})$ by acylation using a C_1-C_4 alkanoyl chloride or bromide, or an alkanoic anhydride of the formula $(C_1-C_4\text{ alkyl}.CO)_2O$;

(iii) reducing a $-CO(C_1-C_4\text{ alkyl})$ substituent to a substituent of the formula $-CH(OH)(C_1-C_4\text{ alkyl})$.

(iv) when R is $-CONH_2$, converting a $-(CH_2)_nCOO(C_1-C_4\text{ alkyl})$ substituent to $-(CH_2)_nCONR^4R^5$ by reaction with ammonia or the appropriate amine R^4R^5NH ;

35 (v) converting a hydroxy substituent to C_1-C_4 alkoxy firstly by reaction with a base such as potassium carbonate, and secondly by reaction with a C_1-C_4 alkyl iodide or bromide;

(vi) converting a hydroxymethyl or hydroxyethyl substituent to $-CH_2NR^4R^5$ or $-(CH_2)_2NR^4R^5$ firstly by reaction with thionyl chloride and secondly by reaction with ammonia or the appropriate amine R^4R^5NH ;

40 (vii) when R is $-CONH_2$, converting a $-CO(C_1-C_4\text{ alkyl})$ substituent to $-C(OH)(C_1-C_4\text{ alkyl})_2$ by reaction with a C_1-C_4 alkylolithium or C_1-C_4 alkylmagnesium bromide, chloride, or iodide;

(viii) converting an iodo substituent to C_1-C_4 alkoxy carbonyl by reaction with carbon monoxide in a C_1-C_4 alkanol containing a base and a palladium (II) catalyst;
and

45 (ix) converting the product of the formula (I) into a pharmaceutically acceptable salt.


14. A process according to claim 13(a), characterised in that (i) the leaving group is Br, Cl, I, C_1-C_4 alkanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy or trifluoromethanesulfonyloxy and (ii) the reaction is carried out in the presence of an acid acceptor.

15. A process according to claim 13(b), characterised in that the hydrolysis is carried out using concentrated aqueous sulphuric acid.

50 16. A process according to any one of claims 13 to 15 characterised in that (i) Y is a direct link, $-CH_2-$, $-(CH_2)_2-$ or $-CH_2O-$ and (ii) R^1 is a group of the formula:-


55

5



where R² and R³ are each independently selected from H, halo, hydroxy, hydroxymethyl, C₁-C₄ alkyl, C₁-C₄ alkoxy and carbamoyl, and X and X¹ are each independently O or CH₂.

10 17. A process according to claim 16, characterised in that Y is -CH₂- and R¹ is a group of the formula:-



15

18. A process according to any one of claims 13 to 17 characterised in that the piperidine starting material is in the 3R or 3RS form.

19. A method of treatment of a human being to cure or prevent a disease associated with the altered motility and/or tone of smooth muscle, such as irritable bowel syndrome, which comprises treating said 20 human being with an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or composition thereof, as claimed in any one of claims 1 to 8 or 9 respectively.

25

30

35

40

45

50

55



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

Application number

EP 89 20 2720

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
D, A	EP-A-0 178 946 (A.H. ROBINS) * Whole document * --	1,12	C 07 D 211/34 C 07 D 405/06 C 07 D 401/06 C 07 D 409/06 C 07 D 405/12 C 07 D 401/12 C 07 D 409/12 A 61 K 31/445
A	CHEMICAL ABSTRACTS, vol. 90, no. 25, 18th June 1979, page 606, abstract no. 203878y, Columbus, Ohio, US, & JP-A-79 03 076 (HOKURIKU PHARMACEUTICAL CO., LTD) 11-01-1979 -----	1,11	
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: 1-18</p> <p>Claims searched incompletely:</p> <p>Claims not searched: 19</p> <p>Reason for the limitation of the search:</p> <p>Method for treatment of the human or animal body by surgery or therapy (See art. 52(4) of the European Patent Convention).</p>			
Place of search	Date of completion of the search	Examiner	
The Hague	06-02-1990	ALLARD	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			